Base de dados : MEDLINE
Pesquisa : E07.505.254 [Categoria DeCS]
Referências encontradas : 3424 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 343 ir para página                         

  1 / 3424 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460835
[Au] Autor:Madularu D; Kumaragamage C; Mathieu AP; Kulkarni P; Rajah MN; Gratton AP; Near J
[Ad] Endereço:Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC, Canada; Brain Imaging Centre, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada. Electronic address: dan.madularu@gmail.com.
[Ti] Título:A chronic in situ coil system adapted for intracerebral stimulation during MRI in rats.
[So] Source:J Neurosci Methods;284:85-95, 2017 Jun 01.
[Is] ISSN:1872-678X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We describe the fabrication and performance of a chronic in situ coil system designed to allow focal brain stimulation in rats while acquiring functional MRI data. NEW METHOD: An implantable receive-only surface radiofrequency coil (iCoil) was designed to be fitted subcutaneously, directly onto to the rat skull surface during the intracerebral cannulation procedure. The coil is fixed in place using acrylic dental cement anchored to four screws threaded into the skull. To demonstrate the use of this coil system in situ, whole-brain functional MRI scans were acquired during various stimuli, including intracranial microinfusions of bicuculline and morphine in the prefrontal cortex and ventral tegmental area, respectively. RESULTS/COMPARISON TO OTHER METHODS: SNR performance of the iCoil was superior to three commercially-available coils, in some instances by a factor of two. Widespread BOLD activation was observed in response to bicuculline and morphine microinfusions. CONCLUSION: A new approach was demonstrated for high-SNR MR imaging of the brain in rats with intracranial implants using an implantable surface coil. This approach enables mapping the functional response to highly targeted stimuli such as intracranial microinfusions.
[Mh] Termos MeSH primário: Encéfalo/diagnóstico por imagem
Estimulação Encefálica Profunda/instrumentação
Estimulação Encefálica Profunda/veterinária
Bombas de Infusão Implantáveis
Imagem por Ressonância Magnética/instrumentação
Imagem por Ressonância Magnética/veterinária
Microinjeções/veterinária
[Mh] Termos MeSH secundário: Animais
Desenho de Equipamento
Análise de Falha de Equipamento
Masculino
Microinjeções/instrumentação
Próteses e Implantes
Ratos
Ratos Long-Evans
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Transdutores/veterinária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  2 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29080577
[Au] Autor:McCrea DL
[Ad] Endereço:Department of Acute and Continuing Care, University of Texas Health Science Center at Houston, School of Nursing, 6901 Bertner Avenue, Suite 695, Houston, TX 77030, USA. Electronic address: Deborah.L.McCrea@uth.tmc.edu.
[Ti] Título:A Primer on Insulin Pump Therapy for Health Care Providers.
[So] Source:Nurs Clin North Am;52(4):553-564, 2017 Dec.
[Is] ISSN:1558-1357
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An estimated 1 million people use an insulin pump to manage their diabetes. Few medical professionals understand or feel comfortable caring for people who use an insulin pump. This article will help the medical professional understand the reasons why the insulin pump helps the user to achieve better glycemic control, have more flexibility, and enjoy a better quality of life. Additionally, this article discusses the advantages, disadvantages, candidate selection, contraindications, basic functions, and troubleshooting of the insulin pump.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Hipoglicemiantes/administração & dosagem
Bombas de Infusão Implantáveis/estatística & dados numéricos
Sistemas de Infusão de Insulina/estatística & dados numéricos
Insulina/administração & dosagem
[Mh] Termos MeSH secundário: Gerenciamento Clínico
Seres Humanos
Atenção Primária à Saúde/organização & administração
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Insulin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM; N
[Da] Data de entrada para processamento:171030
[St] Status:MEDLINE


  3 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834868
[Au] Autor:Yoon YK; Lee KC; Cho HE; Chae M; Chang JW; Chang WS; Cho SR
[Ad] Endereço:aDepartment and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine bDepartment of Medicine, The Graduate School of Yonsei University cRehabilitation Institute of Neuromuscular Disease dDepartment of Neurosurgery and Brain Research Institute, Yonsei University College of Medicine eBrain Korea 21 PLUS Project for Medical Science, Yonsei University fYonsei Stem Cell Research Center, Avison Biomedical Research Center, Seoul, Korea.
[Ti] Título:Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury.
[So] Source:Medicine (Baltimore);96(34):e7472, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intrathecal baclofen (ITB) has been known to reduce spasticity which did not respond to oral medications and botulinum toxin treatment. However, few results have been reported comparing the effects of ITB therapy in patients with cerebral palsy (CP) and acquired brain injury. This study aimed to investigate beneficial and adverse effects of ITB bolus injection and pump therapy in patients with CP and to compare outcomes to patients with acquired brain injury such as traumatic brain injury and hypoxic brain injury. ITB test trials were performed in 37 patients (19 CP and 18 acquired brain injury). Based on ambulatory function, CP patients were divided into 2 groups: 11 patients with nonambulatory CP and 8 patients with ambulatory CP. Change of spasticity was evaluated using the Modified Ashworth Scale. Additional positive or negative effects were also evaluated after ITB bolus injection. In patients who received ITB pump implantation, outcomes of spasticity, subjective satisfaction and adverse events were evaluated until 12 months post-treatment. After ITB bolus injection, 32 patients (86.5%) (CP 84.2% versus acquired brain injury 88.9%) showed a positive response of reducing spasticity. However, 8 patients with CP had negative adverse effects. Particularly, 3 ambulatory CP patients showed standing impairment and 1 ambulatory CP patient showed impaired gait pattern such as foot drop because of excessive reduction of lower extremity muscle tone. Ambulatory CP patients received ITB pump implantation less than patients with acquired brain injury after ITB test trials (P = .003 by a chi-squared test). After the pump implantation, spasticity was significantly reduced within 1 month and the effect maintained for 12 months. Seventeen patients or their caregivers (73.9%) were very satisfied, whereas 5 patients (21.7%) suffered from adverse events showed no subjective satisfaction. In conclusion, ITB therapy was effective in reducing spasticity in patients with CP and acquired brain injury. Before ITB pump implantation, it seems necessary to perform the ITB bolus injection to verify beneficial effects and adverse effects especially in ambulatory CP.
[Mh] Termos MeSH primário: Baclofeno/uso terapêutico
Lesões Encefálicas/tratamento farmacológico
Paralisia Cerebral/tratamento farmacológico
Relaxantes Musculares Centrais/uso terapêutico
Espasticidade Muscular/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Baclofeno/administração & dosagem
Baclofeno/efeitos adversos
Feminino
Seres Humanos
Bombas de Infusão Implantáveis
Injeções Espinhais
Masculino
Limitação da Mobilidade
Relaxantes Musculares Centrais/administração & dosagem
Relaxantes Musculares Centrais/efeitos adversos
Satisfação do Paciente
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Muscle Relaxants, Central); H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007472


  4 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28817499
[Au] Autor:Buxton K; Morgan A; Rogers J
[Ad] Endereço:Ann Morgan, MS RN CPNP, is Nurse Practitioner, Baclofen Pump Program, Boston Children's Hospital, Boston, MA. Jayne Rogers, MSN RN NEA-BC CPHQ, is Nursing Director, Inpatient Medicine Services, Boston Children's Hospital, Boston, MA.
[Ti] Título:Nurse Practitioner Lead Pediatric Baclofen Pump Program: Impact on Safety and Quality of Care.
[So] Source:J Neurosci Nurs;49(5):324-329, 2017 Oct.
[Is] ISSN:1945-2810
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Children with cerebral palsy experience spasticity that can be debilitating and cause significant pain and contractures. Intrathecal baclofen (ITB) therapy can help relieve this spasticity and improve the quality of life for these patients, but it comes with risk. Withdrawal from the medication in case of abrupt discontinuation of delivery can be life-threatening. Regular maintenance of the system is mandatory. Having a program in place to manage the device and support patients helps to ensure their safety. Toward this end, we developed a program with a nurse practitioner (NP) leader to secure the safety and quality of care for patients using ITB therapy. As the program grew, the NP role as an expert in the care and management of ITB pumps became essential to the safety and care of these patients. In addition to the basic outpatient and inpatient management of the baclofen pump, the NP developed a detailed educational program for the patients and leads the quality and safety initiative for the program. The NP is also in a unique position to have intimate knowledge of the patient's condition and build a strong relationship with the patient/family. The NP is able to use this knowledge and relationship as concerns arise that could be related to the ITB therapy. This has greatly improved the safety and quality of care for patients using ITB therapy at our institution.
[Mh] Termos MeSH primário: Baclofeno/uso terapêutico
Bombas de Infusão Implantáveis
Relaxantes Musculares Centrais/uso terapêutico
Profissionais de Enfermagem/normas
Segurança do Paciente
Pediatria
Qualidade da Assistência à Saúde
[Mh] Termos MeSH secundário: Paralisia Cerebral/complicações
Paralisia Cerebral/tratamento farmacológico
Criança
Seres Humanos
Espasticidade Muscular/tratamento farmacológico
Educação de Pacientes como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Muscle Relaxants, Central); H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1097/JNN.0000000000000310


  5 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28651005
[Au] Autor:Watanabe T; Nishimoto T; Mlakar L; Heywood J; Malaab M; Hoffman S; Feghali-Bostwick C
[Ad] Endereço:Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
[Ti] Título:Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis.
[So] Source:PLoS One;12(6):e0179917, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. It has been reported that systemic delivery of BLM via continuous diffusion from subcutaneously implanted osmotic minipumps can cause fibrosis of the skin, lungs, and other internal organs. However, the mouse strain, dosage of BLM, administration period, and additional important features differ from one report to the next. In this study, by employing the pump model in C57BL/6J mice, we show a dose-dependent increase in lung fibrosis by day 28 and a transient increase in dermal thickness. Dermal thickness and the level of collagen in skin treated with high-dose BLM was significantly higher than in skin treated with low dose BLM or vehicle. A reduction in the thickness of the adipose layer was noted in both high and low dose groups at earlier time points suggesting that the loss of the fat layer precedes the onset of fibrosis. High-dose BLM also induced dermal fibrosis and increased expression of fibrosis-associated genes ex vivo in human skin, thus confirming and extending the in vivo findings, and demonstrating that a human organ culture model can be used to assess the effect of BLM on skin. In summary, our findings suggest that the BLM pump model is an attractive model to analyze the underlying mechanisms of fibrosis and test the efficacy of potential therapies. However, the choice of mouse strain, duration of BLM administration and dose must be carefully considered when using this model.
[Mh] Termos MeSH primário: Escleroderma Sistêmico/etiologia
[Mh] Termos MeSH secundário: Animais
Bleomicina/administração & dosagem
Bleomicina/toxicidade
Colágeno Tipo I/genética
Fator de Crescimento do Tecido Conjuntivo/genética
Modelos Animais de Doenças
Fibronectinas/genética
Expressão Gênica/efeitos dos fármacos
Seres Humanos
Bombas de Infusão Implantáveis
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Técnicas de Cultura de Órgãos
Fibrose Pulmonar/etiologia
Fibrose Pulmonar/genética
Fibrose Pulmonar/patologia
Esclerodermia Localizada/etiologia
Esclerodermia Localizada/genética
Esclerodermia Localizada/patologia
Escleroderma Sistêmico/genética
Escleroderma Sistêmico/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Collagen Type I); 0 (Ctgf protein, mouse); 0 (Fibronectins); 0 (collagen type I, alpha 1 chain); 11056-06-7 (Bleomycin); 139568-91-5 (Connective Tissue Growth Factor)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179917


  6 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28592636
[Au] Autor:Linnemann AK; Blumer J; Marasco MR; Battiola TJ; Umhoefer HM; Han JY; Lamming DW; Davis DB
[Ad] Endereço:Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Wisconsin-Madison, Madison, Wisconsin, USA; aklinnem@iu.edu.
[Ti] Título:Interleukin 6 protects pancreatic ß cells from apoptosis by stimulation of autophagy.
[So] Source:FASEB J;31(9):4140-4152, 2017 Sep.
[Is] ISSN:1530-6860
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:IL-6 is a pleiotropic cytokine with complex roles in inflammation and metabolic disease. The role of IL-6 as a pro- or anti-inflammatory cytokine is still unclear. Within the pancreatic islet, IL-6 stimulates secretion of the prosurvival incretin hormone glucagon-like peptide 1 (GLP-1) by α cells and acts directly on ß cells to stimulate insulin secretion Uncovering physiologic mechanisms promoting ß-cell survival under conditions of inflammation and stress can identify important pathways for diabetes prevention and treatment. Given the established role of GLP-1 in promoting ß-cell survival, we hypothesized that IL-6 may also directly protect ß cells from apoptosis. Herein, we show that IL-6 robustly activates signal transducer and activator of transcription 3 (STAT3), a transcription factor that is involved in autophagy. IL-6 stimulates LC3 conversion and autophagosome formation in cultured ß cells. IL-6 infusion stimulates a robust increase in lysosomes in the pancreas that is restricted to the islet. Autophagy is critical for ß-cell homeostasis, particularly under conditions of stress and increased insulin demand. The stimulation of autophagy by IL-6 is regulated multiple complementary mechanisms including inhibition of mammalian target of rapamycin complex 1 (mTORC1) and activation of Akt, ultimately leading to increases in autophagy enzyme production. Pretreatment with IL-6 renders ß cells resistant to apoptosis induced by proinflammatory cytokines, and inhibition of autophagy with chloroquine prevents the ability of IL-6 to protect from apoptosis. Importantly, we find that IL-6 can activate STAT3 and the autophagy enzyme GABARAPL1 in human islets. We also see evidence of decreased IL-6 pathway signaling in islets from donors with type 2 diabetes. On the basis of our results, we propose direct stimulation of autophagy as a novel mechanism for IL-6-mediated protection of ß cells from stress-induced apoptosis.-Linnemann, A. K., Blumer, J., Marasco, M. R., Battiola, T. J., Umhoefer, H. M., Han, J. Y., Lamming, D. W., Davis, D. B. Interleukin 6 protects pancreatic ß cells from apoptosis by stimulation of autophagy.
[Mh] Termos MeSH primário: Apoptose/fisiologia
Autofagia/fisiologia
Células Secretoras de Insulina/metabolismo
Interleucina-6/metabolismo
[Mh] Termos MeSH secundário: Proteínas Adaptadoras de Transdução de Sinal/genética
Proteínas Adaptadoras de Transdução de Sinal/metabolismo
Animais
Linhagem Celular
Diabetes Mellitus Tipo 2
Regulação da Expressão Gênica
Peptídeo 1 Semelhante ao Glucagon/genética
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Seres Humanos
Bombas de Infusão Implantáveis
Interleucina-6/genética
Interleucina-6/farmacologia
Ilhotas Pancreáticas/metabolismo
Masculino
Camundongos
Proteínas Associadas aos Microtúbulos/genética
Proteínas Associadas aos Microtúbulos/metabolismo
Ratos
Proteínas Recombinantes
Transdução de Sinais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adaptor Proteins, Signal Transducing); 0 (GABARAPL1 protein, human); 0 (Interleukin-6); 0 (Microtubule-Associated Proteins); 0 (Recombinant Proteins); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1096/fj.201700061RR


  7 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535970
[Au] Autor:Tabatabaie O; Kasumova GG; Kent TS; Eskander MF; Fadayomi AB; Ng SC; Critchlow JF; Tawa NE; Tseng JF
[Ad] Endereço:Surgical Outcomes Analysis & Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
[Ti] Título:Upper extremity deep venous thrombosis after port insertion: What are the risk factors?
[So] Source:Surgery;162(2):437-444, 2017 Aug.
[Is] ISSN:1532-7361
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Totally implantable venous access devices (ports) are widely used, especially for cancer chemotherapy. Although their use has been associated with upper extremity deep venous thrombosis, the risk factors of upper extremity deep venous thrombosis in patients with a port are not studied adequately. METHODS: The Healthcare Cost and Utilization Project's Florida State Ambulatory Surgery and Services Database was queried between 2007 and 2011 for patients who underwent outpatient port insertion, identified by Current Procedural Terminology code. Patients were followed in the State Ambulatory Surgery and Services Database, State Inpatient Database, and State Emergency Department Database for upper extremity deep venous thrombosis occurrence. The cohort was divided into a test cohort and a validation cohort based on the year of port placement. A multivariable logistic regression model was developed to identify risk factors for upper extremity deep venous thrombosis in patients with a port. The model then was tested on the validation cohort. RESULTS: Of the 51,049 patients in the derivation cohort, 926 (1.81%) developed an upper extremity deep venous thrombosis. On multivariate analysis, independently significant predictors of upper extremity deep venous thrombosis included age <65 years (odds ratio = 1.22), Elixhauser score of 1 to 2 compared with zero (odds ratio = 1.17), end-stage renal disease (versus no kidney disease; odds ratio = 2.63), history of any deep venous thrombosis (odds ratio = 1.77), all-cause 30-day revisit (odds ratio = 2.36), African American race (versus white; odds ratio = 1.86), and other nonwhite races (odds ratio = 1.35). Additionally, compared with genitourinary malignancies, patients with gastrointestinal (odds ratio = 1.55), metastatic (odds ratio = 1.76), and lung cancers (odds ratio = 1.68) had greater risks of developing an upper extremity deep venous thrombosis. CONCLUSION: This study identified major risk factors of upper extremity deep venous thrombosis. Further studies are needed to evaluate the appropriateness of thromboprophylaxis in patients at greater risk of upper extremity deep venous thrombosis.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Bombas de Infusão Implantáveis/efeitos adversos
Neoplasias/tratamento farmacológico
Trombose Venosa Profunda de Membros Superiores/etiologia
Dispositivos de Acesso Vascular/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Feminino
Florida
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Neoplasias/complicações
Neoplasias/patologia
Estudos Retrospectivos
Fatores de Risco
Trombose Venosa Profunda de Membros Superiores/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE


  8 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28381794
[Au] Autor:Matsuyama A; Takatori S; Sone Y; Ochi E; Goda M; Zamami Y; Hashikawa-Hobara N; Kitamura Y; Kawasaki H
[Ad] Endereço:Department of Clinical Pharmaceutical Science, Graduate School of Medicine Pharmaceutical Sciences, Okayama University.
[Ti] Título:Effect of Nerve Growth Factor on Innervation of Perivascular Nerves in Neovasculatures of Mouse Cornea.
[So] Source:Biol Pharm Bull;40(4):396-401, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Angiogenesis, which is the generation of new vascular networks from existing blood vessels, occurs under normal and pathophysiological conditions. Perivascular nerves, which innervate mature vasculatures, maintain vascular tone and regulate tissue blood flow. However, little is known whether perivascular nerves innervate newborn blood vessels. Therefore, the aim of this study was to investigate the distribution and characterization of perivascular nerves in neovasculatures, which were generated by the mouse corneal micropocket method. Under anesthesia, a pellet containing basic fibroblast growth factor (bFGF) (100 ng/pellet) was implanted into a mouse cornea in one side of the eyeball. Nerve growth factor (NGF) was locally (2 or 20 ng) applied with the pellet, or subcutaneously (40 ng/h for 7 d) administered with an osmotic mini-pump. After the implantation, vascular endothelial cells, smooth muscle cells, and perivascular nerves in the cornea were immunohistochemically studied. Neovessels generated from existing limbal vessels were observed in pellet-implanted cornea. Immunostaining of neovasculatures showed the presence of CD31-like immunoreactive (LI) endothelial cells and α-smooth muscle actin-LI vascular smooth muscles. Perivascular nerves immunostained by protein gene product (PGP) 9.5, an axonal marker, were found in the existing limbal vessels, but they were not observed in neovasculatures. Local and subcutaneous treatment of NGF inhibits bFGF-derived angiogenesis and resulted in loop-shaped vessels that had many anastomoses, and produced innervation of PGP 9.5-LI perivascular nerves around bFGF-derived neovessels. These findings suggest that neovasculatures have no innervation of perivascular nerves, and that NGF facilitates innervations of perivascular nerves to regulate the blood flow in neovessels.
[Mh] Termos MeSH primário: Córnea/irrigação sanguínea
Córnea/inervação
Músculo Liso Vascular/irrigação sanguínea
Músculo Liso Vascular/inervação
Neovascularização Fisiológica/efeitos dos fármacos
Fator de Crescimento Neural/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Córnea/efeitos dos fármacos
Bombas de Infusão Implantáveis
Injeções Subcutâneas
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Músculo Liso Vascular/efeitos dos fármacos
Neovascularização Fisiológica/fisiologia
Fibras Nervosas/efeitos dos fármacos
Fibras Nervosas/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9061-61-4 (Nerve Growth Factor)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00583


  9 / 3424 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28379938
[Au] Autor:Liu G; Zhou J; Sun H; Zhang Y; Chen H; Hu S
[Ad] Endereço:State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Beijing, China (mainland).
[Ti] Título:Effects of Cone-Shaped Bend Inlet Cannulas of an Axial Blood Pump on Thrombus Formation: An Experiment and Simulation Study.
[So] Source:Med Sci Monit;23:1655-1661, 2017 Apr 05.
[Is] ISSN:1643-3750
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND Cannula shape and connection style influence the risk of thrombus formation in the blood pump by varying the blood flow characteristics inside the pump. Inlet cannulas should be designed based on the need for anatomical fit and reducing the risk of thrombus generation in the blood pump. The effects on thrombus formation of the cone-shaped bend inlet cannulas of axial blood pumps should be studied. MATERIAL AND METHODS The cannulas were designed as cone-shaped, with 1 bent section connecting 2 straight sections. Both the silicone tube and novel cone-shaped cannula were simulated for comparison. The flow fields of a blood pump with inlet cannula were simulated by computational fluid dynamics (CFD) at flows of 2.0, 2.5, and 3.0 liters per minute (lpm), with pump rotational speeds of 7500, 8000, and 8500 rpm, respectively. Then, 6 two-dimensional (2D) particle image velocimetry (PIV) tests were conducted and the velocity distributions were analyzed. RESULTS A low-velocity region was located inside the pump entrance when a soft silicone tube was used. At 8500 rpm and 3.0 lpm working condition, the minimum velocity inside the pump with cone-shaped cannulas was 2.5×10^-1 m/s. The cone-shaped cannulas eliminated the low-velocity region inside the pump. Both CFD and PIV results showed that the low-velocity region did not spread to the entrance of the blood pump within the flow range from 2.0 lpm to 7.0 lpm. CONCLUSIONS The designed cone-shaped bent cannulas can eliminate the low-velocity region inside the blood pump and reduce the risk of thrombus formation in the blood pump.
[Mh] Termos MeSH primário: Desenho de Equipamento/instrumentação
Coração Auxiliar
Modelos Cardiovasculares
Trombose/prevenção & controle
[Mh] Termos MeSH secundário: Velocidade do Fluxo Sanguíneo/fisiologia
Cânula
Simulação por Computador
Hemodinâmica/fisiologia
Seres Humanos
Hidrodinâmica
Bombas de Infusão Implantáveis
Reologia/instrumentação
Reologia/métodos
Trombose/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE


  10 / 3424 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28353527
[Au] Autor:Woolf SM; Baum CR
[Ad] Endereço:*Fellow (Woolf), Section of Pediatric Emergency Medicine; and †Professor of Pediatrics and of Emergency Medicine (Baum), Yale School of Medicine, New Haven, CT.
[Ti] Título:Baclofen Pumps: Uses and Complications.
[So] Source:Pediatr Emerg Care;33(4):271-275, 2017 Apr.
[Is] ISSN:1535-1815
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intrathecal baclofen therapy, given via an implanted pump in the abdominal wall either as a continuous infusion or bolus dosing, has been used for more than 25 years to treat the spasticity and dystonia associated with various brain and spinal cord conditions. Pediatric clinicians occasionally encounter baclofen pumps, and in the pediatric setting, significant morbidity can arise from their use. This article presents the background, mechanism of action, uses, and complications of intrathecal baclofen therapy and discusses various management strategies should complications occur.
[Mh] Termos MeSH primário: Baclofeno/administração & dosagem
Lesões Encefálicas/tratamento farmacológico
Distonia/tratamento farmacológico
Traumatismos da Medula Espinal/tratamento farmacológico
[Mh] Termos MeSH secundário: Baclofeno/efeitos adversos
Seres Humanos
Bombas de Infusão Implantáveis/efeitos adversos
Reoperação/estatística & dados numéricos
Infecção da Ferida Cirúrgica/epidemiologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.1097/PEC.0000000000001090



página 1 de 343 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde